Sulayman Benmerzoug
Orleans, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Journal: Journal for immunotherapy of cancer
Published: November 30, 2023
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Journal: European urology open science
Published: September 12, 2022
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Journal: Journal for immunotherapy of cancer
Published: August 02, 2022
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Journal: European urology open science
Published: October 15, 2021
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Journal: European urology focus
Published: March 19, 2021
Hippocampal interleukin-33 mediates neuroinflammation-induced cognitive impairments.
Journal: Journal of neuroinflammation
Published: April 06, 2020
Self-DNA Sensing in Lung Inflammatory Diseases.
Journal: Trends in immunology
Published: February 19, 2019
Sterile Lung Inflammation Induced by Silica Exacerbates Mycobacterium tuberculosis Infection via STING-Dependent Type 2 Immunity.
Journal: Cell reports
Published: December 05, 2018
Myeloid cell TNFR1 signaling dependent liver injury and inflammation upon BCG infection.
Journal: Scientific reports
Published: October 18, 2018
STING-dependent sensing of self-DNA drives silica-induced lung inflammation.
Journal: Nature communications
Published: May 17, 2018
GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection.
Journal: Scientific reports
Published: March 09, 2018
Last Updated: 09/26/2026